AN2 Therapeutics, Inc.
Datakwaliteit: 83%
ANTX
Nasdaq
Manufacturing
Chemicals
€ 3,25
▼
€ 0,09
(-2,69%)
Marktkapitalisatie: 116,81 M
Prijs
€ 3,25
Marktkapitalisatie
116,81 M
Dagbereik
€ 3,20 — € 3,35
52-Weeksbereik
€ 1,00 — € 6,91
Volume
119.774
Openen € 3,32
50D / 200D Gem.
€ 2,39
36,24% above
50D / 200D Gem.
€ 1,46
122,19% above
Quick Summary
Belangrijkste Punten
Negative free cash flow of -29,83 M
Groei
Revenue Growth (5Y)
N/A
Revenue (1Y)N/A
Earnings (1Y)N/A
FCF Growth (3Y)N/A
Kwaliteit
Return on Equity
-54,44%
Onder sectorgemiddelde (-53,41%)
ROIC-42,09%
Net MarginN/A
Op. MarginN/A
Veiligheid
Debt / Equity
N/A
Current RatioN/A
Interest CoverageN/A
Waardering
PE (TTM)
-3,32
Onder sectorgemiddelde (-1,48)
P/B Ratio1,93
EV/EBITDAN/A
Dividend YieldN/A
Koershistorie
Financiële Trends
Sectorvergelijking
vs Manufacturing sector mediaan (1364 peers)
Sectorvergelijking
vs Manufacturing sector mediaan (1364 peers)| Metriek | Aandeel | Sector Mediaan |
|---|---|---|
| P/E | -3,3 | -1,5 |
| P/B | 1,9 | 1,6 |
| ROE % | -54,4 | -53,4 |
| Net Margin % | — | -41,5 |
| Rev Growth 5Y % | — | 1,8 |
| D/E | — | 0,3 |
All Fundamental Metrics
All Fundamental Metrics
| Growth | |||
| Revenue Growth (1Y) | N/A | Revenue Growth (3Y) | N/A |
| Earnings Growth (1Y) | N/A | Earnings Growth (3Y) | N/A |
| Revenue Growth (5Y) | N/A | Earnings Growth (5Y) | N/A |
| Profitability | |||
| Revenue (TTM) | N/A | Net Income (TTM) | -35,17 M |
| ROE | -54,44% | ROA | -49,17% |
| Gross Margin | N/A | Operating Margin | N/A |
| Net Margin | N/A | Free Cash Flow (TTM) | -29,83 M |
| ROIC | -42,09% | FCF Growth (3Y) | N/A |
| Safety | |||
| Debt / Equity | N/A | Current Ratio | N/A |
| Interest Coverage | N/A | Asset Turnover | N/A |
| Working Capital | N/A | Tangible Book Value | 60,38 M |
| Dividends | |||
| Dividend Yield | N/A | Payout Ratio | N/A |
| Dividend Growth (3Y) | N/A | Dividend Growth (5Y) | N/A |
| Consecutive Div Years | N/A | ||
| Valuation | |||
| P/E Ratio | -3,32 | Forward P/E | N/A |
| P/B Ratio | 1,93 | P/S Ratio | N/A |
| PEG Ratio | N/A | Forward PEG | N/A |
| EV/EBITDA | N/A | Fwd EV/EBITDA | N/A |
| Forward P/S | N/A | Fwd Earnings Yield | N/A |
| FCF Yield | -25,54% | ||
| Market Cap | 116,81 M | Enterprise Value | 98,81 M |
| Per Share | |||
| EPS (Diluted TTM) | -1,16 | Revenue / Share | N/A |
| FCF / Share | -0,83 | OCF / Share | -0,83 |
| EPS CAGR (1Y) | N/A | EPS CAGR (5Y) | N/A |
| EPS CAGR (10Y) | N/A | ||
| Efficiency | |||
| CapEx / Revenue | N/A | FCF Conversion | 84,82% |
| SBC-Adj. FCF | -36,58 M | Growth Momentum | N/A |
Income Statement
Annual, most recent first
Income Statement
Annual, most recent first| Metric | FY2025 | FY2024 | FY2023 | FY2022 |
|---|---|---|---|---|
| Revenue | — | — | — | — |
| Net Income | -35,17 M | -51,32 M | -64,73 M | -40,96 M |
| EPS (Diluted) | -1,16 | -1,72 | -2,74 | -2,79 |
| Gross Profit | — | — | — | — |
| Operating Income | -38,11 M | -56,79 M | -69,64 M | -42,26 M |
| EBITDA | — | — | — | — |
| R&D Expenses | 24,77 M | 40,49 M | 54,87 M | 28,51 M |
| SG&A Expenses | — | — | — | — |
| D&A | — | — | — | — |
| Interest Expense | — | — | — | — |
| Income Tax | 0,0 | 0,0 | 0,0 | 0,0 |
Balance Sheet
Annual, most recent first
Balance Sheet
Annual, most recent first| Metric | FY2025 | FY2024 | FY2023 | FY2022 |
|---|---|---|---|---|
| Total Assets | 61,95 M | 92,09 M | 138,74 M | 102,56 M |
| Total Liabilities | 8,89 M | 10,24 M | 14,04 M | 7,19 M |
| Shareholders' Equity | 53,06 M | 81,85 M | 124,70 M | 95,37 M |
| Total Debt | — | — | — | — |
| Cash & Equivalents | 19,94 M | 21,35 M | 15,65 M | 27,22 M |
| Current Assets | 59,94 M | 86,26 M | 110,51 M | 98,62 M |
| Current Liabilities | 8,72 M | — | 14,04 M | 7,19 M |
{"event":"ticker_viewed","properties":{"ticker":"ANTX","listing_kind":"stock","pathname":"/stocks/antx","exchange":"Nasdaq","country":"US"}}